PMS Registry
Company Name
Bayer Taiwan Co., Ltd.
Protocol Number
XA1402 (Impact 17237)
Title of Study
Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia
Primary Objective
Following the findings of the clinical trials in drug development, this globalnon-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
Number of Sites
Expected to have 8
Period of Study
From:2014-11-1 to:2016-10-31
Number of Patients
IRB Approval Date
Currently under review
Publication Plan / Date